David A. Siegel En V Veno Medical Corp Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.54 - $6.6 $19,068 - $27,720	-4,200 Reduced 24.0%	13,300 $67,000
Q3 2022 Nov 14, 2022	SELL	$0.1 - $7.82 $1,950 - $152,490	-19,500 Reduced 52.7%	17,500 $110,000
Q2 2022 Aug 15, 2022	SELL	$3.39 - $6.5 $42,714 - $81,900	-12,600 Reduced 25.4%	37,000 $140,000
Q1 2022 May 16, 2022	SELL	$4.42 - $7.0 $138,346 - $219,100	-31,300 Reduced 38.69%	49,600 $316,000
Q4 2021 Feb 14, 2022	BUY	$6.23 - $10.24 $504,007 - $828,416	80,900 New	80,900 $533,000

5.61M

89.3K

5.2K

Ticker NVNO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 9,469,850
Market Cap $24.6M
Description
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.